### RESEARCH ARTICLE

Check for updates **a** OPEN ACCESS

Taylor & Francis Taylor & Francis Group

# **Improving curcumin bactericidal potential against multi-drug resistant bacteria via its loading in polydopamine coated zinc-based metal–organic frameworks**

Abdul Jabbar<sup>a</sup> (D[,](http://orcid.org/0000-0001-9404-5186) Kh[a](#page-0-0)dija Rehman<sup>a</sup>, Too[b](#page-0-1)a Jabri<sup>a</sup>, Tasmina Kanwal<sup>a</sup>, Samina Perveen<sup>b</sup>, Md Abdur Rashid<sup>c[,](http://orcid.org/0000-0002-5611-0378)d</sup>, Mo[h](#page-0-7)sin K[a](#page-0-0)zi<sup>e</sup> **D**, Saeed Ahmad Khan<sup>[f,](#page-0-5)[g](#page-0-6)</sup>, Salim Saifullah<sup>a,h</sup> and Muhammad Raza Shah<sup>a</sup>

<span id="page-0-5"></span><span id="page-0-4"></span><span id="page-0-3"></span><span id="page-0-2"></span><span id="page-0-1"></span><span id="page-0-0"></span><sup>a</sup>H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan; ªH.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan;<br><sup>b</sup>School of Environmental and Biological Engineering, Nanjing University of Sci Pharmaceutics, College of Pharmacy, King Khalid University, Guraiger, Abha, Saudi Arabia; <sup>d</sup>Pharmacy Discipline, Faculty of Health, School of Clinical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia; e Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; <sup>f</sup>Department of Pharmacy, Kohat University of Science and Technology, Kohat, Pakistan; <sup>g</sup>Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA; hPakistan Forest Institute, Peshawar, Pakistan

### <span id="page-0-7"></span><span id="page-0-6"></span>ABSTRACT

Multi-drug resistant (MDR) bactearial strains have posed serious health issues, thus leading to a significant increase in mortality, morbidity, and the expensive treatment of infections. Metal-organic frameworks (MOFs), comprising metal ions and a variety of organic ligands, have been employed as an effective drug deliveryy vehicle due to their low toxicity, biodegradability, higher structural integrity and diverse surface functionalities. Polydopamine (PDA) is a versatile biocompatible polymer with several interesting properties, including the ability to adhere to biological surfaces. As a result, modifying drug delivery vehicles with PDA has the potential to improve their antimicrobial properties. This work describes the preparation of PDA-coated Zn-MOFs for improving curcumin's antibacterial properties against S. aureus and E. coli. Powder X-ray diffraction (P-XRD), FT-IR, scanning electron microscopy (SEM), and DLS were utilized to characterize PDA-coated Zn-MOFs. The curcumin loading and in vitro release of the prepared MOFs were also examined. Finally, the MOFs were tested for bactericidal ability against E. coli and S. aureus using an anti-bacterial assay and surface morphological analysis. Smaller size MOFs were capable of loading and releasing curcumin. The findings showed that as curcumin was encapsulated into PDA-coated MOFs, its bactericidal potential was significantly enhanced, and the findings were further supported by SEM which indicated the complete morphological distortion of the bacteria after treatment with PDA-Cur-Zn-MOFs. These studies clearly indicate that the PDA-Cur-Zn-MOFs developed in this study are extremely promising for long-term release of drugs to treat a wide range of microbial infections.

#### ARTICLE HISTORY

Received 14 October 2022 Revised 6 December 2022 Accepted 11 December 2022

#### **KEYWORDS**

<span id="page-0-8"></span>metal-organic frameworks; Polydopamine coating; characterization; curcumin loading; bactericidal potential

## **1. Introduction**

<span id="page-0-9"></span>Metal-organic frameworks (MOFs) are porous materials having crystalline morphology comprised of organic molecules coordinated with metal ions that can be used to produce three-dimensional structures with unique properties. These materials generally contain active components, the potential for pore functionalization, a high surface-to-volume ratio, and a large pore volume (Furukawa et al., [2013;](#page-10-0) Shah et al., [2022\)](#page-11-0). MOFs have displayed remarkable properties in numerous scientific domains, including gas storage and separation, electrochemistry, sensing, and catalysis, and their potential applications in the field of biomedicine are gaining considerable attention (Li et al., [2009](#page-11-1); Horcajada et al., [2012;](#page-11-2) <span id="page-0-20"></span><span id="page-0-19"></span><span id="page-0-17"></span><span id="page-0-16"></span><span id="page-0-15"></span><span id="page-0-14"></span><span id="page-0-12"></span><span id="page-0-11"></span><span id="page-0-10"></span>Morozan and Jaouen, [2012;](#page-11-3) Baumann et al., [2019;](#page-10-1) Meteku et al., [2021\)](#page-11-4). The compositional diversity of these materials permits the development of theranostics, contrast agents, and drug delivery systems with an acceptable toxicity profile (Horcajada et al., [2006;](#page-11-5) [2010;](#page-11-6) Rojas et al., [2019\)](#page-11-7). Zinc (II) is among the most commonly employed cations in MOFs design. Secondary building units, typically endless rod-like structures or discrete clusters, have evolved as a result of the wide range of coordination geometries enabled by its electrical arrangement, which ranges from four- to six-sided polyhedral (Tranchemontagne et al., [2009](#page-11-8); Schoedel et al., [2016\)](#page-11-9). Zinc (II) is a component of several important enzymes and transcription factors, making it an essential nutrient with a daily intake of 10 mg (Shankar and Prasad, [1998](#page-11-10); Trumbo

<span id="page-0-18"></span><span id="page-0-13"></span>CONTACT Muhammad Raza Shah a [raza.shah@iccs.edu](mailto:raza.shah@iccs.edu) **international Center for Chemical and Biological Sciences, H.E.J. Research Institute of Chemistry,** University of Karachi, 74200 Karachi, Pakistan; Md Abdur Rashid @ [mdrashid@kku.edu.sa](mailto:mdrashid@kku.edu.sa) @ Department of Pharmaceutics, College of Pharmacy, King Khalid University, Guraiger, Abha 62529, Saudi Arabia; Pharmacy Discipline, Faculty of Health, School of Clinical Sciences, Queensland University of Technology, Brisbane, QLD 4000, Australia

This is an Open Access article distributed under the terms of the Creative Commons Attribution License [\(http://creativecommons.org/licenses/by/4.0/\)](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

<sup>© 2023</sup> The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

<span id="page-1-19"></span><span id="page-1-14"></span><span id="page-1-2"></span>et al., [2001](#page-12-0)). It plays an important role in oxidative stress response, immunological response, aging, apoptosis, DNA replication and damage repair, and protein synthesis, including collagen production (Chasapis et al., [2020\)](#page-10-2). Zinc's toxicity has also been investigated extensively, and the oral lethal dose for humans is approximately 3 g/kg of body weight (Roney et al., [2006](#page-11-11); Plum et al., [2010\)](#page-11-12). Zn is also an antioxidant mineral because, as a cation, it is redox inactive and does not promote the formation of reactive oxygen species (Shankar and Prasad, [1998;](#page-11-13) Chasapis et al., [2020\)](#page-10-3). Antibacterial efficacy is affected by concentration and contact time. Zinc's antimicrobial effects are due to direct contact with microbial membranes, coordination with nucleic acids, and respiratory system inhibition (Pasquet et al., [2014](#page-11-14)).

<span id="page-1-25"></span><span id="page-1-18"></span><span id="page-1-16"></span><span id="page-1-12"></span><span id="page-1-11"></span><span id="page-1-7"></span><span id="page-1-4"></span><span id="page-1-0"></span>Polydopamine (PDA) has drawn significant interest in a variety of sectors due to its adaptable hydrophilicity, biocompatibility, and adhesion capability and has been utilized to modify the surface of porous materials without altering their pore shape (Hebbar et al., [2016;](#page-11-15) Hou et al., [2021;](#page-11-16) Jadidi et al., [2022\)](#page-11-17). Self-polymerization of dopamine in a mildly alkaline tris-buffer solution modifies different substrates by adding water-holding phenolic OH and NH moieties (Barclay et al., [2017\)](#page-10-4). In addition to its antifungal and antibacterial properties against a wide range of microorganisms, PDA has also been used to treat cancer (Zhou et al., [2021](#page-12-1)). The development of a simple shaking-assisted process has facilitated the fabrication of roughened PDA (rPDA) coatings on a variety of substrates (Singh et al., [2021\)](#page-11-18). When compared to the control coatings, rPDA coatings exhibit much higher antimicrobial potential against a variety of bacteria, both Gram-negative and Gram-positive, without the use of an external antibacterial agent (Su et al., [2016](#page-11-19)). PDA coatings can be utilized to manipulate antibacterial activity by utilizing a range of buffers, as the buffer selection can influence the amount of a certain functional group present in the PDA coating (Patel et al., [2018](#page-11-20)). PDA coatings mediated by sodium hydroxide and tris were found to have higher antibacterial activity than coatings mediated by phosphate-buffered saline (PBS) and sodium bicarbonate (Patel et al., [2018](#page-11-21)). This difference could be explained by the presence of an increased number of surface hydroxyl groups in the latter. It was discovered that different chemistries had different effects on the physicochemical characteristics and morphology of the PDA coatings, which in turn had different effects on the antibacterial or antifouling activities of the coatings (Zhou et al., [2014](#page-12-2)). Recently, PDA coating on the surface of nanocarriers has received considerable interest in the development of nanocarriers, particularly in the preparation of MOFs. This is due to the availability of several functional groups in PDA, namely amine and catechol, which make it a suitable platform for the co-ordination of metal ions (Yang et al., [2016\)](#page-12-3). In a similar manner, Jiajing Zhou et al., designed PDA coated nanohybrids that consisted of a MOFs shell and a nanoparticle core (Yang et al., [2016\)](#page-12-4). In a study published by Isabelle I. Niyonshuti et al., the PDA-AgNPs were developed with a controllable PDA coating thickness to examine the impact of the surface on the antibacterial activity of the AgNPs (Niyonshuti et al., [2020](#page-11-22)). Therefore, PDA has been selected

as the surface coating material because of its excellent adhesive properties.

<span id="page-1-21"></span><span id="page-1-17"></span><span id="page-1-13"></span><span id="page-1-8"></span><span id="page-1-6"></span><span id="page-1-3"></span><span id="page-1-1"></span>Infectious diseases caused by bacteria are one of the world's leading health concerns, affecting millions of individuals each year. Antibiotic-resistant bacterial infections are becoming more common and pose a severe threat to public health (Koch et al., [2014](#page-11-23); Willyard, [2017](#page-12-5); Cheng et al., [2019](#page-10-5)). Antibiotics are the most extensively used and efficient way of preventing and treating bacterial diseases (Spellberg et al., [2013\)](#page-11-24). However, antibiotic overuse and misuse have resulted in the emergence and spread of antibiotic-resistant microorganisms (Brown and Wright, [2016](#page-10-6)). Moreover, bacterial colonization and biofilm formation by sessile microbial populations represent a significant clinical problem (Iwase et al., [2010\)](#page-11-25). Therefore, alternative therapeutic approaches for bacterial infections and biofilms are urgently required to prevent the evolution of antibiotic resistance. Antibacterial activity of curcumin (CUR) has been discovered at nontoxic and safe levels in recent years (Zorofchian Moghadamtousi et al., [2014;](#page-12-6) Shome et al., [2016\)](#page-11-26). There are numerous hypotheses regarding the mechanism by which CUR destroys bacteria. According to Tyagi et al., CUR can inhibit bacterial growth by rupturing the bacterial membrane (Tyagi et al., [2015\)](#page-12-7). Lee et al., studied the CUR's antibacterial mechanism, which they found to be mediated by an apoptotic-like response (Yun and Lee, [2016\)](#page-12-8). However, due to CUR's poor water solubility, fast breakdown, and poor oral bioavailability, its therapeutic potential is limited (Mahmood et al., [2015](#page-11-27); Yallapu et al., [2015](#page-12-9)). The development of an efficient nano-carrier technology for the purpose of resolving issues associated with CUR is extremely desirable in order to enhance its antibacterial activity.

<span id="page-1-27"></span><span id="page-1-24"></span><span id="page-1-22"></span><span id="page-1-20"></span><span id="page-1-15"></span><span id="page-1-9"></span><span id="page-1-5"></span>In this study, PDA-coated CUR-loaded MOFs (PDA-CUR-Zn-MOFs) were prepared in order to improve the efficacy of CUR and increase its action against bacteria. PDA was employed to modify the surface of MOFs in order to enhance their adherence to bacterial cells, which in turn inhibits the growth of bacteria. The PDA-CUR-Zn-MOFs were analyzed using various techniques, including FT-IR, SEM, Powder X-ray diffraction, and DLS. The antibacterial activity of the PDA-CUR-Zn-MOFs was tested on two different bacterial strains. In addition, SEM was performed to investigate the attachment of PDA-CUR-Zn-MOFs to bacteria and to determine the structural and morphological variations in the bacteria after treatment with PDA-CUR-Zn-MOFs.

#### <span id="page-1-26"></span>**2. Experimental**

### *2.1. Materials and methods*

<span id="page-1-23"></span><span id="page-1-10"></span>For this experiment, analytical-grade solvents were bought from Sigma Aldrich (Germany). Rueddel-deHaen (Germany) provided the 99.9% pure Zn(OAc)2.2H2. Moreover, terephthalic acid, dopamine, and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) were acquired from Sigma Aldrich (Germany). The tryptic soya agar (TSA) and Mueller Hinton broth (MHB) were provided by Oxoid, UK. Bosch Pharmaceuticals (Pvt) Ltd. in Pakistan graciously supplied the CUR that was utilized in this investigation.

### *2.2. Preparation of zinc-terephthalate MOFs (Zn-MOFs)*

<span id="page-2-3"></span>The Zn-MOFs were synthesized using a previously published method (Ghasemzadeh et al., [2018](#page-10-7)), with a few modifications. Briefly, one mmol of terephthalic acid and two mmol of zinc acetate dihydrate were dissolved in ten mL of dimethylformamide (DMF), which was then stirred and mixed. After 2.5 hours of stirring at room temperature, 0.3 mL of triethylamine was mixed to the solution. The orange-yellow precipitates were obtained by centrifugation for 10 minutes at 5000 rpm, washed with ethanol and DMF to separate any residual solvent, and then dried in a vacuum oven. [Figure 1](#page-2-0) depicts a schematic representation of Zn-MOFs synthesis (Tella et al., [2020\)](#page-11-28).

### <span id="page-2-6"></span><span id="page-2-2"></span>*2.3. Encapsulation of curcumin in Zn-MOFs (CUR-Zn-MOFs)*

In order to encapsulate CUR, 60 mg of Zn-MOFs dispersion in distilled water (6 mL) and 30 mg of CUR solution in methanol (4 mL) were mixed. The mixture was then stirred at 200 rpm for 24 hours. Thus, the CUR was encapsulated in Zn-MOFs. The prepared CUR-Zn-MOFs were then collected by centrifugation at 10,000 rpm for 15 minutes. The free CUR was measured at 420nm in the supernatant utilizing a UV-Vis spectrophotometer (UV-240, Shimadzu, Japan). The % drug encapsulation efficiency (%DEE) was measured utilizing the formula below (Kanwal et al., [2019](#page-11-29)).

Total amount of drug–Amount of  
\n
$$
\%DEE = \frac{free drug in the supernatant}{Total amount of drug} \times 100
$$

### *2.4. Preparation of PDA coated CUR-Zn-MOFs (PDA-CUR-Zn-MOFs)*

<span id="page-2-5"></span>A previously published method was adopted to generate PDA-coated CUR-Zn-MOFs, with minor changes (Shan et al., [2020\)](#page-11-30). Briefly, 19 mg of dopamine was dissolved in a Tris buffer solution (10 mM, pH 8.5) while stirring. The solution was stirred for 24 hours after adding 25 mg of Cur-Zn-MOFs. PDA-CUR-Zn-MOFs were produced by centrifuging the resulting solid for 10 minutes at 10,000 rpm, thoroughly washing it using water, and then oven-dried it for 6hours at 50 °C. The schematic representation for the preparation of PDA-CUR-Zn-MOFs is depicted in [Scheme 1.](#page-2-1)

### *2.5. Characterization*

### *2.5.1. Zeta potential, size, polydispersity index (PDI), and surface morphology*

After being diluted with distilled water, the samples were examined in triplicate on a zeta-sizer (Nano ZS90, Malvern Instruments, UK) to evaluate particle size, zeta potential, and PDI at 25°C and a scattering angle of 90. SEM was performed

<span id="page-2-4"></span>

<span id="page-2-0"></span>**[Figure 1.](#page-2-2)** Schematic illustration of the synthesis of Zn-MOFs.



<span id="page-2-1"></span>**Scheme 1.** Synthesis routs for the preparation of PDA-CUR-Zn-MOFs.

to evaluate the surface morphology of the developed MOFs. During the SEM analysis, samples were gold-coated at temperatures of up to 300°A, and then images were captured using a Japanese JEOL microscope (Model number JSM-6380A).

#### *2.5.2. FTIR analysis*

FT-IR analysis of Zn-MOFs, dopamine, PDA-CUR-Zn-MOFs, CUR, and CUR-Zn-MOFs was performed by an infrared spectrophotometer (Shimadzu, Kyoto). The samples were mixed with KBr pellets and compressed to a pressure of  $1.38 \times 10^3$  kPa to form disks. Between 400 and 4000 cm−1, the IR spectra of the formed disks were recorded.

#### *2.5.3. Powder X-ray diffraction (P-XRD)*

The purity, size, and crystallinity of the prepared Zn-MOFs were examined using the P-XRD method. From 5° to 60° (2θ), diffraction patterns were evaluated utilizing an X-ray diffraction instrument (Axios Petro, PANalytical, Co Kα, λ=1.79021) with Cu-Kα irradiation.

#### *2.5.4. Analysis of in vitro drug release*

In order to perform the drug release study, PDA-CUR-Zn-MOFs (5 mg) were dispersed in sterile water and then poured into a dialysis bag. The dialysis bag was then immersed in 30mL of buffer solution with a pH of 6.8 in an Erlenmeyer flask. At predetermined intervals, 2 mL of the dissolution medium were separated and replaced with 2mL of a fresh solution. A UV-Vis-Spectrophotometer was employed to measure the released CUR in the obtained samples at 420 nm (Motakef-Kazemi et al., [2014\)](#page-11-31).

#### <span id="page-3-1"></span>*2.6. Antibacterial assay*

#### *2.6.1. Bacterial strains*

Two ATCC bacterial strains, S. aureus (ATCC 6538) and E. coli (ATCC 10536) were derived from the organism under study, and their antibacterial activity was evaluated in the laboratory. The stock cultures were stored in TSA at 4° C. Before the antibacterial analysis, the bacterial strains were subcultured for 24hours on fresh, appropriate agar. Several single-microbe colonies were injected into an inert MHB to create inocula. To confirm that the bacterial cells in suspension had reached a final density of  $5 \times 10^5$  cfu/mL, viable cell counts were performed. In 1 mL of solution, there were  $10<sup>5</sup>$  colony-forming units (cfu), which is the infectious dose for the majority of bacteria.

### *2.6.2. Assessment of minimum inhibitory concentration (MIC)*

<span id="page-3-0"></span>As described previously (Khan et al., [2021](#page-11-32)), a Tetrazolium microplate assay was carried out to measure the MIC of both the reference materials and the bacteria that were subjected to the standard test. The experiment was conducted on a transparent 96-well microliter plate. Bacterial cell suspensions  $(5x10<sup>5</sup>cfu/mL)$  of S. aureus and E. coli were used to inoculate the wells immediately after harvest. Zn-MOFs, CUR, PDA-CUR-Zn-MOFs, and CUR-Zn-MOFs were serially diluted in MBH from 250µg to 10µg, and 200µl of each concentration were then added in triplicate wells before the mixture was incubated at  $37^{\circ}$ C ± 0.5 for 18 to 24 hours. Following that, MTT (50µl, 0.2mg/mL) was put to all wells and incubated at 37 °C for 30 min. A bacterial culture served as the positive control in this experiment, while DMSO served as the negative control. After DMSO was added, the concentration of the dye was determined utilizing a spectrophotometer with a reference wavelength of 650nm and absorbance at 570nm (indicating the inhibition of bacterial growth) (Sarkar et al., [2007\)](#page-11-33).

<span id="page-3-3"></span>
$$
IC50 = \frac{O.D. \text{ in Control} - O.D. \text{ of test}}{O.D. \text{ in control}} \times 100
$$

# *2.6.3. Minimum biofilm inhibitory concentration (MBIC) determination*

<span id="page-3-2"></span>Microplate experiments were performed to compare the antibiofilm abilities of PDA-CUR-Zn-MOFs, CUR-Zn-MOFs, Zn-MOFs, and CUR against E. coli and S. aureus. The aforementioned prepared substances were diluted in the same manner as previously stated and then placed in a 96-well flat bottom plate (Corning, USA). An inoculum of 5x10<sup>5</sup> CFU mL<sup>-1</sup> of bacteria was injected into all wells except the well containing the control broth. Plates were stained after an overnight incubation at 37 °C to identify biofilm formation (O'Toole et al., [1999\)](#page-11-34). To remove any remaining planktonic cells, the plates were cleaned three times with sterile water and stained for 20 minutes with crystal violet at a concentration of 0.1% (w/v). To eliminate the crystal violet that had been retained by the biofilms, the plates were rinsed again and then treated with a 30% (v/v) solution of glacial acetic acid. The microplate reader (Tecan, USA) determined the plates' absorbance at 590 nm. The following formula was employed to determine the percentage of inhibition of biofilms.

%biofilm inhibition =  $\frac{O.D. \text{ in Control} - O.D. \text{ of test}}{O.D. \text{ in control}} \times 100$ 

#### *2.6.4. Analysis of the surface morphology*

The surface morphology of biofilms was studied using SEM. Changes in the morphology of exponentially growing E. coli and S. aureus cell suspensions (5x10<sup>5</sup> CFU/mL) in response to a test samples were observed. MBIC microliter plates with the appropriate wells were used to collect the samples (5–10 µL), and drug-free cells worked as the control. As previously mentioned, the cells were pelleted and then fixed in a glutaraldehyde (2%) solution at 4°C for 2 hours. The cells were dehydrated utilizing increasing concentrations of alcohols. After applying a gold coating, samples were analyzed utilizing a JSM-6380A SEM.

### *2.7. Statistical analysis*

All experiments were performed in three times, and the results were given as the mean $\pm$ SEM.

#### **3. Result and discussion**

### *3.1. Characterization*

#### *3.1.1. Size, zeta-potential and PDI*

<span id="page-4-6"></span><span id="page-4-5"></span>DLS was performed to determine the PDI, size and zeta potential of PDA-CUR-Zn-MOFs, CUR-Zn-MOFs, and Zn-MOFs. Particle size has a direct effect on the physical stability and therapeutic efficacy of encapsulated drugs, making it one of the most crucial and essential component of drug-delivery pharmacological formulations. MOFs are a subset of the larger category of porous crystalline nanomaterials, and the size of these materials can be precisely controlled by the fabrication method and solvent. It has been demonstrated that DMF creates particles that are even smaller than methanol and water (Khan et al., [2021\)](#page-11-35). Cross-linkers utilized during production make MOFs more amenable to dissolution in DMF (Chalati et al., [2011\)](#page-10-8). The particle size of Zn-MOFs was observed to be  $200.9 \pm 18$  nm with a PDI of  $0.233 \pm 0.08$ ; after CUR loading and PDA coating, the particle size increased to  $220.8 \pm 14$  nm with a PDI of  $0.317 \pm 0.02$  and  $294.7 \pm 04$  nm with a PDI of  $0.329 \pm 0.064$ , as shown in [Table 1](#page-4-0) and Figure 2. When the CUR was encapsulated and PDA was coated on the Zn-MOFs, the PDI increased, indicating the MOFs' uneven CUR loading and PDA coating. The Zeta potential is also crucial to drug delivery vehicles because it reveals information about the particles' total net charge. The zeta potential of Zn-MOFs was determined to be −7.50±0.04 due to the use of terephthalic acid as a cross-linker during their production. The surface charges of Zn-MOFs were found to increase slightly after PDA coating and CUR encapsulation  $(-9.38 \text{ mV} \pm 0.06 \text{ and } -11.4 \text{ mV} \pm 0.08$ , respectively). Increases in the zeta potential value are anticipated to improve the physical stability of MOFs because particles with identical increased charges are believed to repel one another and remain suspended ([Figure 3](#page-5-0)). In addition, coating by PDA ensures that the drug remains intact within Zn-MOFs.

#### <span id="page-4-3"></span>*3.1.2. Surface morphology*

<span id="page-4-4"></span>The SEM was utilized to examine the surface morphology of the prepared Zn-MOFs. Before drug loading, the Zn-MOFs displayed a smooth, crystalline surface ([Figure 4A](#page-5-1)). [Figure 4B](#page-5-1) demonstrates that the surface roughened slightly after drug loading and became entirely rough after PDA coating [\(Figure 4C\)](#page-5-1). The drug experiences considerable morphological changes during loading and PDA coating, which may be suggestive of a partial breakdown of the framework. Drug-loaded MOFs had a more inflated morphology than empty MOFs, suggesting that the drug had been entrapped into the holes of the MOFs. These findings also demonstrated that drug-loaded MOFs were less porous and more densely filled than empty MOFs.

#### <span id="page-4-2"></span>*3.2. Drug encapsulation efficiency*

<span id="page-4-7"></span>The encapsulation of drugs in the developed drug-delivery carrier guarantees the delivery of therapeutics to the selective point with increased efficacy. Since the entrapment occurs primarily in the tunnels and cages of MOFs, the incorporation of the drug candidate in those structures is essentially determined by their surface area (Shen et al., [2017](#page-11-36)). The CUR

<span id="page-4-0"></span>**Table 1.** Size, PDI, Zeta potential, and encapsulation efficiency of prepared Zn-MOFs. Test Sample Size (nm) PDI Zeta Potential (mV) % EE  $Zn-MOFs$  200.9 $\pm 18$  0.233 $\pm 0.08$   $-7.50\pm 0.04$   $\begin{array}{cccc}\n\text{CUR-Zn-MOFs} & 220.8 \pm 14 & 0.317 \pm 0.02 & -9.38 \pm 0.06 & 80.04 \pm 1.46\% \\
\text{PDA-CUR-Zn-MOFs} & 294.7 \pm 04 & 0.329 \pm 0.064 & -11.4 \pm 0.08 & 75.66 \pm 2.24\% \end{array}$ PDA-CUR-Zn-MOFs  $294.7 + 04$   $0.329 + 0.064$ 



<span id="page-4-1"></span>**[Figure 2.](#page-4-2)** Size distribution of Zn-MOFs (A), CUR-Zn-MOFs (B), and PDA-CUR-Zn-MOFs (C).



<span id="page-5-0"></span>**[Figure 3.](#page-4-3)** Zeta potential of Zn-MOFs (A), CUR-Zn-MOFs (B), and PDA-CUR-Zn-MOFs (C).



**[Figure 4.](#page-4-4)** SEM images of Zn-MOFs (A), CUR-Zn-MOFs (B), and PDA-CUR-Zn-MOFs (C).

<span id="page-5-1"></span>loaded content into the prepared Zn-MOFs was  $80.04 \pm 1.46\%$ . The encapsulation mechanism in the Zn-MOFs may require the adsorption of CUR on their surfaces or the inclusion in their holes through secondary interactions (hydrogen bonding and pi–pi stacking). After being coated with PDA, Zn-MOFs' encapsulation efficiency slightly decreased ([Table 1](#page-4-0)) which may be associated with the elimination of CUR that were weakly bound with Zn-MOFs during the PDA functionalization process.

### *3.3. FT-IR analysis*

<span id="page-5-2"></span>The CUR loading, PDA coating, and Zn-MOFs synthesis were evaluated by FT-IR analysis. In the FT-IR spectrum of terepthalic acid, an absorption peak at 3250 cm<sup>-1</sup> region corresponds to the O-H group and a significant absorption peak was observed at 1660 cm<sup>-1</sup> corresponds to the C=O group of carboxylic acid [\(Figure 5A](#page-6-0)). The FT-IR spectrum of prepared Zn-MOFs did not exhibit the significant peak of terephthalic acid at 3250cm−1 because of coordination with zinc. Moreover, after coordination with Zn, a little shift in absorption frequency from 1660 cm−1 to 1652 cm−1 was seen. The FT-IR spectra of CUR exhibited the typical peaks of  $O-H$  and  $C=O$ at 3520 cm−1 and 1626 cm−1, respectively, clearly demonstrating the interaction of CUR with the produced Zn-MOFs ([Figure 5C](#page-6-0)). After being incorporated in Zn-MOFs, the significant peak of Zn-MOFs was slightly moved to 3450cm−1 along with decreased intensity. In addition, the presence of CUR in the Zn-MOFs was confirmed by the appearance of the significant peak of  $C = O$  of CUR in the loaded Zn-MOFs ([Figure 5D](#page-6-0)). The O-H signal was occurred at 3329 cm−1 in the FTIR spectrum of dopamine, while benzene ring was identified at 1615 cm−1 ([Figure 5E](#page-6-0)). As shown in [Figure 5F](#page-6-0), the corresponding functional groups were submerged in the surface coating process, as the normal dopamine peak at 3329 cm−1 was disappeared whereas a prominent peak at 3183 cm−1 was found after modification.

#### *3.4. Powder-XRD*

Powder-XRD is considered as an efficient technique to examine the crystallinity of materials. The P-XRD spectrum of



<span id="page-6-0"></span>**[Figure 5.](#page-5-2)** FTIR spectrum of terepthalic acid (A), Zn-MOFs (B), curcumin (C), CUR-Zn-MOFs (D), Dopamine (E), and PDA-CUR-Zn-MOFs (F).

<span id="page-6-6"></span><span id="page-6-5"></span>Zn-MOFs exhibited the high intensity Bragg diffraction peaks at  $2\theta = 7.67^{\circ}$ , 18.17°, 21.26°, 26.16°, 32.76° and 37.14° ([Figure 5A](#page-6-0)) as reported previously (Dikio and Farah, [2013\)](#page-10-9). Upon CUR loading, some structural changes appeared in the XRD spectrum with the prominent peak at  $2\theta = 18.98^\circ$  and 27.81° attributing to the presence of crystalline CUR that are adsorbed on the surface of MOFs structure as reported previously (Chen et al., [2018](#page-10-10)). Furthermore, some changes in the intensities ratio of Bragg reflections can be observed, most likely because of changes in interatomic distances and bond angles, or the preferential orientation of crystallites imposed during the drug loading process and filling of pores by CUR, resulting in a partial loss of crystallinity, as shown in [Figure 5B](#page-6-0)



<span id="page-6-1"></span>**[Figure 6.](#page-6-2)** P-XRD of the synthesized Zn-MOFs (A), CUR-Zn-MOFs (B), and PDA-CUR-Zn-MOFs (C).

<span id="page-6-8"></span><span id="page-6-4"></span>(Motakef-Kazemi et al., [2014](#page-11-37); Blanita et al., [2015](#page-10-11)). Interestingly, the structure of CUR-Zn-MOFs was almost unaffected by the PDA coating, but the intensity of the characteristic peak was reduced that are showing the change in crystallinity [\(Figure 5C](#page-6-0)) which is primarily associated with the formation of PDA layer on the surface of MOFs structure (Liu et al., [2018](#page-11-38)). Hence, the observed results revealed the semicrystalline structure for PDA-CUR-Zn-MOFs and CUR-Zn-MOFs ([Figure 6\)](#page-6-1).

#### <span id="page-6-7"></span><span id="page-6-2"></span>*3.5. Analysis of in vitro drug release*

<span id="page-6-3"></span>[Figure 7](#page-7-0) shows the drug release pattern conducted at physiological pH of 6.8. The prepared PDA-CUR-Zn-MOFs exhibited an initial release of  $17.45 \pm 5.64\%$  CUR after 1 h, followed by controlled release behavior for 24 h with a maximum release of  $33.12 \pm 6.10$ %. Initial rapid release may be affiliated to weakly-bound CUR diffusing across the surface of Zn-MOFs. While the CUR incorporated in the pores and linked through interaction with the aromatic ring promoted the extended-release behavior. The release profile of PDA-CUR-Zn-MOFs suggested that it may be suitable for applications that required a high initial dose followed by a maintained release.

### *3.6. Antibacterial analysis*

Tetrazolium microplate testing was utilized for each sample to assess the antibacterial activity in terms of MIC, Half-maximal Inhibitory Concentration ( $IC_{50}$ ), and MBIC values. MIC is defined as the lowest concentration that effectively



<span id="page-7-0"></span>**[Figure 7.](#page-6-3)** In vitro release profile of PDA-CUR-Zn-MOFs at pH 6.8.



<span id="page-7-1"></span>**[Figure 8.](#page-7-2)** MIC and IC50 value of CUR, Zn-MOFs, CUR-Zn-MOFs and PDA-CUR-Zn-MOFs against S. aureus (A, B), and against E. coli (C, D).

<span id="page-7-5"></span><span id="page-7-4"></span>stops the observable growth of bacteria (Rehman et al., [2021\)](#page-11-39). The concentration at which 50% of the bacteria are inhibited is referred to as the  $IC_{50}$ , while the MBIC is the minimum concentration of the antibacterial agent that prevents the initial production of biofilm (Mohamed et al., [2018;](#page-11-40) Ghaffar et al., [2019](#page-10-12)). The results of the provided terms have been thoroughly discussed below.

### <span id="page-7-3"></span>*3.6.1. Determination of MIC value*

A tetrazolium microplate assay was employed to evaluate the MIC for each sample. CUR had a MIC of  $11.5 \pm 0.5 \,\mu$ g/mL and Zn-MOFs had a MIC of  $13.8 \pm 0.8 \,\mu$ g/mL against S. aureus, but when the bacteria was treated with CUR-loaded Zn-MOFs, the MIC was reduced to  $10 \pm 0.4$  µg/mL. Additionally, the MIC <span id="page-7-2"></span>value for S. aureus was further reduced to  $8.18 \pm 0.6\%$  µg/ mL after treatment with PDA-CUR-Zn-MOFs, ([Figure 8A\)](#page-7-1). CUR's IC<sub>50</sub> against S. aureus cells was determined to be  $57.69 \pm 0.5$  µg/mL, while Zn-MOFs exhibited an IC<sub>50</sub> of 69.44  $\pm$  0.8 µg/mL. As depicted in [Figure 8B,](#page-7-1) the value of CUR-Zn-MOFs against S. aureus was reduced to  $50 \pm 0.4 \,\mathrm{\mu g}$ / mL, and it was further decreased to  $40.9 \pm 0.6 \,\mu$ g/mL after modification with PDA.

MIC values for CUR and Zn-MOFs against E. coli were  $15.38 \pm 0.5$ % and  $20 \pm 0.5$  µg/mL respectively. As displayed in [Figure 8C](#page-7-1), the MIC value was significantly decreased for both PDA-CUR-MOFs and CUR-Zn-MOFs, which were determined to be  $9.09\pm0.6$  and  $13.20\pm0.6$  µg/mL, respectively. CUR had an IC50 of  $76.92 \pm 0.5 \,\mu$ g/mL against E. coli cells, while Zn-MOFs had an IC50 of  $100 \pm 0.5$  µg/mL; however, the value



<span id="page-8-0"></span>**[Figure 9.](#page-9-0)** MBIC and IC50 value of CUR, Zn-MOFs, CUR-Zn-MOFs and PDA-CUR-Zn-MOFs against S. aureus (A, B), and against E. coli (C, D).



<span id="page-8-1"></span>**[Figure 10.](#page-9-1)** S. aureus control (A), S. aureus CUR treated (B), S. aureus Zn-MOFs treated (C), S. aureus CUR-Zn-MOFs treated (D), and S. aureus PDA- CUR-Zn-MOFs treated (E).

for cells treated with CUR-Zn-MOFs was reduced to 66.03±0.6% µg/mL, and for PDA-coated CUR-Zn-MOFs was further decreased to  $45.45 \pm 0.6 \,\mu\text{g/mL}$ . When PDA was coated onto CUR-Zn-MOFs, the IC50 value of all of the tested bacterial strains was further reduced as shown in [Figure 8D](#page-7-1). The previously reported MIC value for CUR against S. aureus and



<span id="page-9-2"></span>**[Figure 11.](#page-9-3)** E. coli control (A), E. coli CUR treated (B), E. coli Zn-MOFs treated (C), E. coli CUR-Zn-MOFs treated (D), and E. coli PDA- CUR-Zn-MOFs treated (E).

<span id="page-9-7"></span><span id="page-9-5"></span>E. coli was determined to be 100µg/mL (Gao et al., [2020\)](#page-10-13). The antibacterial activity of PDA, which was measured to be 90 µg/mL against both S. aureus and E. coli was not promising in a prior study published by Indu Singh., et al. However, the PDA surface modification of the nanocomposites significantly reduced the growth of bacteria with a MIC value of less than 30 µg/mL against both strains (Zhang et al., [2022\)](#page-12-10). The increased antibacterial activity of PDA-CUR-Zn-MOFs was attributed to the fact that PDA may facilitate drug permeation into bacterial cells by enhancing cell permeability. Furthermore, ROS (reactive oxygen species), including the well-known disinfectants hydrogen peroxide (H2°2) and superoxide anions (O2-), formed by the oxidation of catechol moieties hindered the growth of bacteria (Zhang et al., [2022](#page-12-11)). Thus, the study found that the bactericidal activity of CUR was much enhanced when it was encapsulated in PDA-coated Zn-MOFs. This is because the interaction between PDA coatings and surface characteristics can considerably alter the antibacterial properties (Singh et al., [2021](#page-11-18)).

### *3.6.2. Assessment of MBIC value*

<span id="page-9-6"></span><span id="page-9-4"></span><span id="page-9-0"></span>Biofilms are the most common kind of microbial life because they allow bacteria to survive in harsh environments (Taylor et al., [2014\)](#page-11-41). Antibiotic-resistant bacteria often thrive in biofilm environments (Dantas et al., [2008](#page-10-14)). Consequently, the MBIC value of prepared Zn-MOFs was also studied against both strains. For S. aureus, the MBIC for CUR was  $37 \pm 0.7$   $\mu$ g/ mL, while the MBIC for Zn-MOFs was  $45 \pm 1.2 \,\mu$ g/mL. CUR's MBIC was decreased to  $17.85 \pm 0.5$  µg/mL and  $16.66 \pm 0.6$  µg/ mL after being encapsulated in Zn-MOFs and modified with PDA, respectively [\(Figure 9A](#page-8-0)). CUR had an  $IC_{50}$  of 185 ± 0.7 µg/ mL against S. aureus cells, while Zn-MOFs had a greater  $IC_{50}$ of 227.27±1.2 µg/mL against S. aureus, while CUR-Zn-MOFs had an IC<sub>50</sub> of 89.28 ± 0.5 µg/mL, which was further decreased to  $62.5 \pm 0.6 \,\mu$ g/mL after PDA coating, as displayed in [Figure 9B](#page-8-0).

The MIC values for CUR and Zn-MOFs against E. coli were  $43.10\pm0.8$  µg/mL and  $37.73\pm0.5$  µg/mL, respectively (Figure [9C\)](#page-8-0). After CUR loading and PDA coating on the prepared Zn-MOFs, these values were dropped to  $19.23 \pm 0.4$  µg/mL and 13.15 $\pm$ 0.6 µg/mL, respectively. The IC<sub>50</sub> values for CUR against E. coli were  $215.5 \pm 0.8 \,\mu$ g/mL, 188.5 $\pm$ 0.5  $\mu$ g/mL for Zn-MOFs,  $996.1 \pm 0.4 \mu q/mL$  for CUR-Zn-MOFs, and 65.78±0.6 µg/mL for PDA coated CUR-Zn-MOFs [\(Figure 9D\)](#page-8-0). Increased antibacterial property of CUR in PDA-CUR-Zn-MOFs was caused by the interaction of PDA coating, which are capable to regulate surface properties and may have a major impact on antibacterial activities (Singh et al., [2021\)](#page-11-42).

#### *3.6.3. Surface morphological study*

<span id="page-9-3"></span><span id="page-9-1"></span>Morphological studies of both E. coli and S. aureus strains were performed using SEM to evaluate the effectiveness of the synthesized MOFs. The morphological alterations that occurred in the bacterial strains after being exposed to the prepared samples are shown in [Figures 10](#page-8-1) and [11](#page-9-2). S. aureus control group morphology was identified as a smooth spherical shape with an agglomerated colony as displayed in [Figure 10A.](#page-8-1) Following treatment with CUR, S. aureus cells lost some of their surface smoothness, and the colony became disturbed, but after treatment with Zn-MOFs, the cells kept their morphology while the agglomerated colony somewhat distasted as displayed in [Figure 10B and C](#page-8-1). Minor

changes in bacterial morphology were observed after treatment with CUR-Zn-MOFs ([Figure 10D](#page-8-1)), but significant changes were observed when the cells were exposed to PDA-CUR-Zn-MOFs ([Figure 10E](#page-8-1)). Synergistic improvement of CUR's effectiveness against S. aureus may be attributed to PDA's tendency to modify membrane permeability and bacterial cell destruction (Iqbal et al., [2012\)](#page-11-43).

<span id="page-10-16"></span>Similarly, treatment of the E. coli strain with all of the test samples exhibited similar results, with the bacterial strains showing morphological alterations. [Figure 11A](#page-9-2) depicts the smooth rod-like surface morphology of the control E. coli strain, whereas [Figure 11B and C](#page-9-2) illustrate the effects of CUR and Zn-MOFs on the morphological characteristics of the bacterial strains, respectively. [Figure 11D and 11E](#page-9-2) show that after being exposed to Cur-Zn-MOFs and PDA-CUR-Zn-MOFs, the rod-shaped bacterial cells were completely distorted (Khan et al., [2021](#page-11-44)). This may be attributed to the generation of ROS by the catechol moieties of PDA, which may have triggered the obstruction of internal matrix in the external environment by attaching to the bacterial cell surface, leading to cell disruption (Guo et al., [2014\)](#page-11-45). According to a recent study, PDA prevents bacteria from extruding metabolic waste and absorbing nutrients, which has an immediate impact on the survival of the bacteria (Iqbal et al., [2012](#page-11-46)). These findings demonstrated conclusively that PDA's excellent bio-adhesive activity significantly contributed to an efficient bacterial cell growth distortion.

### <span id="page-10-15"></span>**4. Conclusion**

In this work, we have successfully prepared Zn-MOFs and modified them with a biocompatible polymer (PDA). The prepared MOFs were capable of encapsulating excess amount of CUR, and exhibited enhanced antibacterial activity of CUR against E. coli and S. aureus. Interestingly, surface modification with PDA notably decreased the MIC and MBIC value of CUR-Zn-MOFs. The findings were further supported by analyzing the surface morphology via SEM, which exhibited the complete distortion of bacterial cells after treatment with PDA-CUR-Zn-MOFs. Conclusively, this study demonstrated that the PDA-coated Zn-MOFs have the potential to control the MDR of bacteria, making them a potential antibacterial alternative for use in preclinical settings for the cure of wide range of bacterial infections.

#### **Acknowledgement**

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Khalid University for supporting this research through the group (large) research programe under grant number RGP 2/70/43.

### **Author contribution**

Conceptualization, AJ., and MRS.; methodology, AJ. and KR; software, AJ., KR., TJ.; formal analysis, MRS., SP., TK, and SS.; investigation, MRS., MK, SAK and TK; writing—original draft preparation, AJ. and KR.; writing—review and editing, MRS., TK., TJ., MAR and SS; visualization, MRS., MK., SP., and SAK; supervision, MRS., and MAR.

### **Data availability statement**

The data supporting this work are accessible upon reasonable request from the corresponding author.

#### **Disclosure statement**

No potential conflict of interest was reported by the authors.

#### **Funding**

This research was funded by the Deanship of Scientific Research at King Khalid University for funding this work through group (large) research program under grant number RGP 2/70/43

#### **ORCID**

Abdul Jabbar **b** <http://orcid.org/0000-0001-9404-5186> Mohsin Kazi D <http://orcid.org/0000-0002-5611-0378>

#### **References**

- <span id="page-10-4"></span>Barclay TG, Hegab HM, Clarke SR, Ginic-Markovic M. ([2017](#page-1-0)). Versatile surface modification using polydopamine and related polycatecholamines: Chemistry, structure, and applications. Adv Mater Interfaces 4:1.
- <span id="page-10-1"></span>Baumann AE, Burns DA, Liu B, Thoi VS. ([2019\)](#page-0-8). Metal-organic framework functionalization and design strategies for advanced electrochemical energy storage devices. Commun Chem 2:14.
- <span id="page-10-11"></span>Blanita G, Mihet M, Borodi G, Misan I, Coldea I, Lupu D. [\(2015](#page-6-4)). Ball milling and compression effects on hydrogen adsorption by MOF: Pt/ carbon mixtures. Microporous Mesoporous Mater 203:195–12.
- <span id="page-10-6"></span>Brown ED, Wright GD. ([2016](#page-1-1)). Antibacterial drug discovery in the resistance era. Nature 529:336–43.
- <span id="page-10-8"></span>Chalati T, Horcajada P, Gref R, Couvreur P, Serre C. [\(2011](#page-4-5)). Optimisation of the synthesis of MOF nanoparticles made of flexible porous iron fumarate MIL-88A. J Mater Chem 21:2220–7.
- <span id="page-10-3"></span><span id="page-10-2"></span>Chasapis CT, Ntoupa P-SA, Spiliopoulou CA, Stefanidou ME. [\(2020](#page-1-2)). Recent aspects of the effects of zinc on human health. Arch Toxicol 94:1443–60.
- <span id="page-10-10"></span>Chen J, Qin X, Zhong S, Chen S, Su W, Liu Y. [\(2018\)](#page-6-5). Characterization of curcumin/cyclodextrin polymer inclusion complex and investigation on its antioxidant and antiproliferative activities. Molecules 23:1179.
- <span id="page-10-5"></span>Cheng W, Zeng X, Chen H, Li Z, Zeng W, Mei L, Zhao Y. [\(2019\)](#page-1-3). Versatile polydopamine platforms: synthesis and promising applications for surface modification and advanced nanomedicine. Acs Nano 13:8537–65.
- <span id="page-10-14"></span>Dantas G, Sommer MO, Oluwasegun RD, Church GMJ. ([2008\)](#page-9-4). Bacteria subsisting on antibiotics. Science 320:100–3.
- <span id="page-10-9"></span>Dikio ED, Farah AM. ([2013\)](#page-6-6). Synthesis, characterization and comparative study of copper and zinc metal organic frameworks. Chem Sci Trans 2:1386–94.
- <span id="page-10-0"></span>Furukawa H, Cordova KE, O'Keeffe M, Yaghi OM. [\(2013\)](#page-0-9). The chemistry and applications of metal-organic frameworks. Science 341:1230444.
- <span id="page-10-13"></span>Gao M, Long X, Du J, Teng M, Zhang W, Wang Y, Wang X, Wang Z, Zhang P, Li J. [\(2020](#page-9-5)). Enhanced curcumin solubility and antibacterial activity by encapsulation in PLGA oily core nanocapsules. Food Funct 11:448–55.
- <span id="page-10-12"></span>Ghaffar I, Imran M, Perveen S, Kanwal T, Saifullah S, Bertino MF, Ehrhardt CJ, Yadavalli VK, Shah MR. ([2019\)](#page-7-3). Synthesis of chitosan coated metal organic frameworks (MOFs) for increasing vancomycin bactericidal potentials against resistant S. aureus strain. Mater Sci Eng C Mater Biol Appl 105:110111.
- <span id="page-10-7"></span>Ghasemzadeh MA, Abdollahi-Basir MH, Mirhosseini-Eshkevari B. ([2018\)](#page-2-3). Multi-component synthesis of spiro [diindeno [1, 2-b: 2′, 1′-e] pyridine-11, 3′-indoline]-triones using zinc terephthalate metal-organic frameworks. Green Chem Lett Rev 11:47–53.
- <span id="page-11-45"></span>Guo Z, Xue J, Liu T, Song X, Shen Y, Wu H. [\(2014\)](#page-10-15). Antibacterial mechanisms of silica/polydopamine/silver nanoparticles against gram positive and gram negative bacteria. Micro & Nano Letters 9:210–4.
- <span id="page-11-15"></span>Hebbar RS, Isloor AM, Ananda K, Ismail A. ([2016\)](#page-1-4). Fabrication of polydopamine functionalized halloysite nanotube/polyetherimide membranes for heavy metal removal. J Mater Chem A 4:764–74.
- <span id="page-11-6"></span>Horcajada P, Chalati T, Serre C, Gillet B, Sebrie C, Baati T, Eubank JF, Heurtaux D, Clayette P, Kreuz C, Chang JS, Hwang YK, Marsaud V, Bories NH, Cynober L, Gil S, Férey G, Couvreur P, Gref R. ([2010](#page-0-10)). Porous metal–organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater 9:172–8.
- <span id="page-11-2"></span>Horcajada P, Gref R, Baati T, Allan PK, Maurin G, Couvreur P, Férey G,Morris RE, Serre C. [\(2012\)](#page-0-11). Metal–organic frameworks in biomedicine. Chem Rev 112:1232–68.
- <span id="page-11-5"></span>Horcajada P, Serre C, Vallet‐Regí M, Sebban M, Taulelle F, Férey G. [\(2006\)](#page-0-12). Metal–organic frameworks as efficient materials for drug delivery. Angew Chem 118:6120–4.
- <span id="page-11-16"></span>Hou M, Zhong Y, Zhang L, Xu Z, Kang Y, Xue P. [\(2021\)](#page-1-5). Polydopamine (PDA)-activated cobalt sulfide nanospheres responsive to tumor microenvironment (TME) for chemotherapeutic-enhanced photothermal therapy. Chin Chem Lett 32:1055–60.
- <span id="page-11-46"></span>Iqbal Z, Lai EP, Avis TJ. ([2012](#page-10-16)). Antimicrobial effect of polydopamine coating on Escherichia coli. J Mater Chem 22:21608–12.
- <span id="page-11-25"></span>Iwase T, Uehara Y, Shinji H, Tajima A, Seo H, Takada K, Agata T, Mizunoe Y. [\(2010\)](#page-1-6). Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 465:346–9.
- <span id="page-11-17"></span>Jadidi A, Shokrgozar MA, Sardari S, Maadani AM. [\(2022\)](#page-1-7). Gefitinib-loaded polydopamine-coated hollow mesoporous silica nanoparticle for gastric cancer application. Int J Pharm 629:122342.
- <span id="page-11-29"></span>Kanwal T, Kawish M, Maharjan R, Ghaffar I, Ali HS, Imran M, Perveen S, Saifullah S, Simjee SU, Shah MR. ([2019](#page-2-4)). Design and development of permeation enhancer containing self-nanoemulsifying drug delivery system (SNEDDS) for ceftriaxone sodium improved oral pharmacokinetics. J Mol Liq 289:111098.
- <span id="page-11-44"></span>Khan A, Aslam F, Kanwal T, Shah MR, Khalil AA, Shah SW, Alshammari EM, El-Masry EA, Batiha GE, Baty RS. [\(2021](#page-3-0)). Enhanced antibacterial potential of Amoxicillin against Helicobacter pylori mediated by lactobionic acid coated Zn-MOFs. Antibiotics 10:1071.
- <span id="page-11-35"></span>Khan A, Ghaffar I, Baty RS, Abdel-Daim MM, Habib SM, Kanwal T, Shah MR. ([2021\)](#page-4-6). A synthesis of ribose-coated copper-based metal–organic framework for enhanced antibacterial potential of chloramphenicol against multi-drug resistant bacteria. Antibiotics 10:1469.
- <span id="page-11-23"></span>Koch G, Yepes A, Förstner KU, Wermser C, Stengel ST, Modamio J, Ohlsen K, Foster KR, Lopez D. ([2014](#page-1-8)). Evolution of resistance to a last-resort antibiotic in Staphylococcus aureus via bacterial competition. Cell 158:1060–71.
- <span id="page-11-1"></span>Li J-R, Kuppler RJ, Zhou H-C. ([2009\)](#page-0-13). Selective gas adsorption and separation in metal–organic frameworks. Chem Soc Rev 38:1477–504.
- <span id="page-11-38"></span>Liu W, Yan Z, Ma X, Geng T, Wu H, Li Z. [\(2018\)](#page-6-7). Mg-MOF-74/MgF2 composite coating for improving the properties of magnesium alloy implants: hydrophilicity and corrosion resistance. Materials 11:396.
- <span id="page-11-27"></span>Mahmood K, Zia KM, Zuber M, Salman M, Anjum MN. ([2015\)](#page-1-9). Recent developments in curcumin and curcumin based polymeric materials for biomedical applications: A review. Int J Biol Macromol 81:877–90.
- <span id="page-11-4"></span>Meteku BE, Huang J, Zeng J, Aslam S, Zhang Y, Zhang X, Cui B, Wen CY, Yan Z. ([2021\)](#page-0-14). Magnetic rod-based metal-organic framework metal composite as multifunctional nanostirrer with adsorptive, peroxidase-like and catalytic properties. Chin Chem Lett 32:3245–51.
- <span id="page-11-40"></span>Mohamed MA, Nasr M, Elkhatib WF, Eltayeb WN. [\(2018\)](#page-7-4). In vitro evaluation of antimicrobial activity and cytotoxicity of different nanobiotics targeting multidrug resistant and biofilm forming Staphylococci. Biomed Res Int 2018:7658238.
- <span id="page-11-3"></span>Morozan A, Jaouen F. [\(2012\)](#page-0-15). Metal organic frameworks for electrochemical applications. Energy Environ Sci 5:9269–90.
- <span id="page-11-31"></span>Motakef-Kazemi N, Shojaosadati SA, Morsali A. ([2014\)](#page-3-1). In situ synthesis of a drug-loaded MOF at room temperature. Microporous Mesoporous Mater 186:73–9.
- <span id="page-11-37"></span>Motakef-Kazemi N, Shojaosadati SA, Morsali AJM. [\(2014\)](#page-6-8). and materials, m. In situ synthesis of a drug-loaded MOF at room temperature. Microporous mesoporous materials [Database]. 186:73–79.
- <span id="page-11-22"></span>Niyonshuti II, Krishnamurthi VR, Okyere D, Song L, Benamara M, Tong X, Wang Y, Chen J. [\(2020](#page-1-10)). Polydopamine surface coating synergizes the antimicrobial activity of silver nanoparticles. ACS Appl Mater Interfaces 12:40067–77.
- <span id="page-11-34"></span>O'Toole GA, Pratt LA, Watnick PI, Newman DK, Weaver VB, Kolter R. ([1999\)](#page-3-2). Genetic approaches to study of biofilms. Methods Enzymol 310:91–109. i.e. [6].
- <span id="page-11-14"></span>Pasquet J, Chevalier Y, Pelletier J, Couval E, Bouvier D, Bolzinger MX. ([2014\)](#page-1-11). The contribution of zinc ions to the antimicrobial activity of zinc oxide. Colloids Surf, A 457:263–74.
- <span id="page-11-21"></span><span id="page-11-20"></span>Patel K, Singh N, Yadav J, Nayak JM, Sahoo SK, Lata J, Chand D, Kumar S, Kumar R. ([2018\)](#page-1-12). Polydopamine films change their physicochemical and antimicrobial properties with a change in reaction conditions. Phys Chem Chem Phys 20:5744–55.
- <span id="page-11-12"></span>Plum LM, Rink L, Haase H. [\(2010\)](#page-1-13). The essential toxin: impact of zinc on human health. Int J Environ Res Public Health 7:1342–65.
- <span id="page-11-43"></span><span id="page-11-39"></span>Rehman K, Ali I, El-Haj BM, Kanwal T, Maharjan R, Saifullah S, Imran M, Shafiullah, Simjee SU, Shah MR. [\(2021\)](#page-7-5). Synthesis of novel biocompatible resorcinarene based nanosized dendrimer-vesicles for enhanced anti-bacterial potential of quercetin. J Mol Liq 341:116921.
- <span id="page-11-7"></span>Rojas S, Arenas-Vivo A, Horcajada P. [\(2019\)](#page-0-16). Metal-organic frameworks: A novel platform for combined advanced therapies. Coord Chem Rev 388:202–26.
- <span id="page-11-11"></span>Roney N, Osier M, Paikoff SJ, Smith CV, Williams M, Rosa CT. ([2006\)](#page-1-14). ATSDR evaluation of the health effects of zinc and relevance to public health. Toxicol Ind Health 22:423–93.
- <span id="page-11-33"></span>Sarkar A, Parikh N, Hearn SA, Fuller MT, Tazuke SI, Schulz C. ([2007\)](#page-3-3). Antagonistic roles of Rac and Rho in organizing the germ cell microenvironment. Curr Biol 17:1253–8.
- <span id="page-11-9"></span>Schoedel A, Li M, Li D, O'Keeffe M, Yaghi OM. ([2016\)](#page-0-17). Structures of metal–organic frameworks with rod secondary building units. Chem Rev 116:12466–535.
- <span id="page-11-32"></span><span id="page-11-0"></span>Shah M, Rehman K, Khan A, Farid A, Marini C, Cerbo AD. ([2022](#page-0-18)). Characterization and antibacterial evaluation of biodegradable Mannose-Conjugated Fe-MIL-88NH2 composites containing vancomycin against methicillin-resistant Staphylococcus aureus strains. Polymers 14:2712.
- <span id="page-11-30"></span>Shan Y, Xu C, Zhang H, Chen H, Bilal M, Niu S, Cao L, Huang Q. ([2020\)](#page-2-5). N. Polydopamine-modified metal–organic frameworks, NH2-Fe-MIL-101, as pH-sensitive nanocarriers for controlled pesticide release. Nanomaterials 10:2000.
- <span id="page-11-13"></span><span id="page-11-10"></span>Shankar AH, Prasad AS. ([1998](#page-0-19)). Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr 68:447S–63S.
- <span id="page-11-36"></span>Shen S, Wu Y, Liu Y, Wu D. [\(2017\)](#page-4-7). High drug-loading nanomedicines: progress, current status, and prospects. Int J Nanomedicine 12:4085–109.
- <span id="page-11-26"></span>Shome S, Talukdar AD, Choudhury MD, Bhattacharya MK, Upadhyaya H. ([2016\)](#page-1-15). Curcumin as potential therapeutic natural product: a nanobiotechnological perspective. J Pharm Pharmacol 68:1481–500.
- <span id="page-11-42"></span><span id="page-11-18"></span>Singh I, Dhawan G, Gupta S, Kumar P. [\(2021](#page-1-16)). Recent advances in a polydopamine-mediated antimicrobial adhesion system. Front Microbiol 11:3326.
- <span id="page-11-24"></span>Spellberg B, Bartlett JG, Gilbert DN. ([2013\)](#page-1-17). The future of antibiotics and resistance. N Engl J Med 368:299–302.
- <span id="page-11-19"></span>Su L, Yu Y, Zhao Y, Liang F, Zhang X. [\(2016\)](#page-1-18). Strong antibacterial polydopamine coatings prepared by a shaking-assisted method. Sci Rep 6:24420–8.
- <span id="page-11-41"></span>Taylor PK, Yeung AT, Hancock RE. ([2014](#page-9-6)). Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies. J Biotechnol 191:121–30.
- <span id="page-11-28"></span>Tella A, Eliagwu S, Amali M, Kola-Mustapha A, Olatunji S, Ishola F, Adimula V, Oluwafemi O. [\(2020](#page-2-6)). Synthesis and characterization of amino and cyano-functionalized zinc-terephthalate metal–organic frameworks for loading of piroxicam drug. Chem Pap 74:2287–96.
- <span id="page-11-8"></span>Tranchemontagne DJ, Mendoza-Cortés JL, O'Keeffe M, Yaghi OM. ([2009\)](#page-0-20). Secondary building units, nets and bonding in the chemistry of metal–organic frameworks. Chem Soc Rev 38:1257–83.
- <span id="page-12-0"></span>Trumbo P, Yates AA, Schlicker S, Poos M. ([2001](#page-1-19)). Dietary reference intakes. J Am Diet Assoc 101:294–301.
- <span id="page-12-7"></span>Tyagi P, Singh M, Kumari H, Kumari A, Mukhopadhyay K. ([2015\)](#page-1-20). Bactericidal activity of curcumin I is associated with damaging of bacterial membrane. PloS One 10:e0121313.
- <span id="page-12-5"></span>Willyard C. [\(2017](#page-1-21)). The drug-resistant bacteria that pose the greatest health threats. Nature 543:15.
- <span id="page-12-9"></span>Yallapu MM, Nagesh PKB, Jaggi M, Chauhan SC. ([2015](#page-1-22)). Therapeutic applications of curcumin nanoformulations. AAPS J 17:1341–56.
- <span id="page-12-4"></span>Yang Z, Wu Y, Wang J, Cao B, Tang CY. ([2016](#page-1-23)). In situ reduction of silver by polydopamine: A novel antimicrobial modification of a thin-film composite polyamide membrane. Environ Sci Technol 50:9543–50.
- <span id="page-12-8"></span>Yun DG, Lee DG. [\(2016](#page-1-24)). Antibacterial activity of curcumin via apoptosis-like response in Escherichia coli. Appl Microbiol Biotechnol 100:5505–14.
- <span id="page-12-11"></span><span id="page-12-10"></span>Zhang W, Huang Y, Wu H, Dou Y, Li Z, Zhang H. ([2022](#page-9-7)). Polydopamine-heparin complex reinforced antithrombotic and antimicrobial activities of heparinized hydrogels for biomedical applications. Compos Part A: Appl Sci Manufacturing 157:106908.
- <span id="page-12-1"></span>Zhou L, Du C, Zhang R, Dong C. ([2021](#page-1-25)). Stimuli-responsive dual drugs-conjugated polydopamine nanoparticles for the combination photothermal-cocktail chemotherapy. Chin Chem Lett 32:561–4.
- <span id="page-12-3"></span><span id="page-12-2"></span>Zhou P, Deng Y, Lyu B, Zhang R, Zhang H, Ma H, Lyu Y, Wei S. ([2014\)](#page-1-26). Rapidly-deposited polydopamine coating via high temperature and vigorous stirring: formation, characterization and biofunctional evaluation. PLoS One 9:e113087.
- <span id="page-12-6"></span>Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi K. ([2014](#page-1-27)). A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int 2014:186864.